FDA: SARS-CoV-2 Mutations May Impact Molecular Tests
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.